Innocoll to Report Second Quarter 2016 Financial Results and Host Webcast and Conference Call on August 17, 2016
August 11 2016 - 4:01PM
Innocoll Holdings plc (Nasdaq:INNL), a global, specialty
pharmaceutical company with late stage development programs
targeting areas of significant unmet medical need, today announced
that it will report second quarter financial results before the
open of U.S. financial markets on August 17, 2016. Innocoll
management will host a webcast and conference call at 8:30 a.m. ET
that day to discuss the financial results and provide a corporate
update.
Interested parties may access the live webcast
and call through the Investors section of the company website at
www.innocoll.com or directly through the registration link. A
recording will be archived on the company website for 90 days.
The live call may be accessed by dialing
877-407-4018 for domestic callers and 201-689-8471 for
international callers. A telephone replay of the call will be
available until 11:59 p.m. EDT on August 20, 2016 by dialing
877-870-5176 for domestic callers or 858-384-5517 for international
callers and entering the conference code:
89801826.
About Innocoll Holdings plc
Innocoll is a global, commercial-stage,
specialty pharmaceutical company that is dedicated to engineering
better medicines to help patients get better. Our proprietary,
biocompatible, and biodegradable collagen products are
precision-engineered for targeted use. Applied locally to wound
and/or surgery sites, they are designed to provide a range of
benefits. The company's late stage product pipeline is focused on
addressing a number of large unmet medical needs, including:
XARACOLL® for the treatment of postoperative pain; COGENZIA
(INL-002), a gentamicin-collagen topical matrix for the adjuvant
treatment of diabetic foot infections; and COLLAGUARD (INL-003), a
barrier for the prevention of post-surgical adhesions.
Our currently approved products include:
COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E,
REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®, some of which are
sold globally through strategic partnerships, including those with
Takeda, EUSA Pharma, Biomet 3i and Biomet. All of our native
collagen products —from extraction/purification of type-1 collagen
through final delivery form — are manufactured at our certified,
integrated plant in Saal, Germany.
For more information, please visit www.innocoll.com.
CollaRx®, Collatamp®, COLLAGUARD®, Collieva®, CollaCare®, Collexa®,
COGENZIA® LidoColl®, LiquiColl®, and XARACOLL® are registered
trademarks, and CollaPress™, DermaSil™, Durieva™, and Zorpreva™ are
trademarks of the company.
Contact:
Pepe Carmona
Chief Financial Officer
(215) 983-3362
pcarmona@innocoll.com
Jeannie Sorenson, M.D.
Vice President, Investor Relations
(314) 458-7355
jsorenson@innocoll.com
Innocoll AG (NASDAQ:INNL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Innocoll AG (NASDAQ:INNL)
Historical Stock Chart
From Sep 2023 to Sep 2024